Evogene Schedules First Quarter 2026 Financial Results Release
Evogene (NASDAQ: EVGN) will release its Q1 2026 financial results on Wednesday, May 20, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evogene (NASDAQ: EVGN) will release its Q1 2026 financial results on Wednesday, May 20, 2026. Management will host a live Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel). Registration is required: https://www.veidan-conferencing.com/evogene. A replay will be posted on the company's website a few days after the call.
Details
News Market Reaction – EVGN
On May 7, the day this news came out, EVGN closed 1.31% below the previous close.
Data tracked by StockTitan Argus for the May 7 session.
Key Figures
- 2025 operating loss
- $14.0 million
- From 2025 annual report (Form 20-F)
- 2024 operating loss
- $18.8 million
- From 2025 annual report (Form 20-F)
- 2023 operating loss
- $22.2 million
- From 2025 annual report (Form 20-F)
- Registered warrant shares
- 5,076,924 shares
- Ordinary shares registered for resale under F-3
- Potential warrant proceeds
- $6.35 million
- If 5,076,924 warrants exercised in full for cash
- Warrants exercise price
- $1.25 per share
- Outstanding warrants disclosed in 20-F
- Shares outstanding
- 9,893,764 shares
- Ordinary shares outstanding as of Mar 15, 2026
- Beneficial ownership limit
- 4.99%
- Ownership cap applicable to registered warrants
Previous Earnings Reports
-
Reported 2025 results with continued operating and net losses plus restructuring.
-
Announced date and call details for Q4 and full-year 2025 results.
-
Set timetable and Zoom call for Q3 2025 financial results release.
-
Reported Q2 2025 results with higher H1 revenue and lower expenses amid restructuring.
-
Announced Q2 2025 results date and investor conference call logistics.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Zoom conference call scheduled for May 20, 2026, 9:00 AM ET
REHOVOT,
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance:
https://www.veidan-conferencing.com/evogene
The entire conference will be available online on the company's website a few days after.
About Evogene:
Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for drug development and ag chemical products.
At the core of its technology is ChemPass AI™, a proprietary generative AI designed to explore vast chemical space and generate novel, highly potent small molecules optimized across multiple critical parameters. Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products for the pharmaceutical and agricultural industries, driven by the integration of scientific innovation with real-world industry needs.
For more information, please visit www.evogene.com.
Contact
ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-schedules-first-quarter-2026-financial-results-release-302765447.html
SOURCE Evogene
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.